{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-045176","form_type":"8-K","ticker":"ALKS","cik":"0001520262","company_name":"Alkermes plc.","filed_at":"2023-08-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.180652+00:00","generated_at":"2026-06-11T01:57:42.166066+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"litigation","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Alkermes settles VIVITROL patent litigation with Teva; generic entry January 2027","bullets":["Teva granted license to market generic VIVITROL in U.S. starting Jan 15, 2027, or earlier under certain circumstances.","Settlement resolves lawsuit filed Sep 2020; trial completed Mar 2023; patent expires 2029.","Agreement subject to FTC and DOJ review; parties will file joint stipulation to dismiss litigation.","Financial terms not disclosed; license is non-exclusive, royalty-free, limited to Teva's ANDA product."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-045176","json":"https://secwatch.observer/filing/0000950170-23-045176.json","markdown":"https://secwatch.observer/filing/0000950170-23-045176.md","text":"https://secwatch.observer/filing/0000950170-23-045176.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1520262/000095017023045176/0000950170-23-045176-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1520262/000095017023045176/alks-20230829.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T01:57:42.166066+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bb78ab1faf9f9c71852d4927ac8a8131d8f74f5b","claim":"Alkermes plc. entered into Confidential Settlement and License Agreement with Teva Pharmaceuticals USA, Inc. (effective 2023-08-29).","evidence_excerpt":"On August 29, 2023, Alkermes, Inc. and Alkermes Pharma Ireland Limited, subsidiaries of Alkermes plc (together, “Alkermes”), entered into a Confidential Settlement and License Agreement (the “Settlement Agreement”) with Teva Pharmaceuticals USA, Inc. (“Teva”, and together with Alkermes, the “parties”) relating to Alkermes’ product VIVITROL ® (naltrexone for extended-release injectable suspension).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1520262/000095017023045176/0000950170-23-045176-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"settlement"},{"label":"Counterparty","value":"Teva Pharmaceuticals USA, Inc."},{"label":"Effective","value":"2023-08-29"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}